drugset / Trial / NCT01510951

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

NCT01510951 ↗

Phase 1 Completed 9 enrolled Amgen
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.

Timeline

Start
2011-08
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 811 Monoclonal antibody — Subcutaneous

Indications